Our therapies


SafeR allows for intelligent management of AV conduction, significantly reducing unnecessary RV pacing in all pacemaker patients, including AV block patients.1–8


AutoMRI mode is the world’s first pacemaker technology capable of detecting an MRI field and automatically switching to asynchronous mode.


Proactive management of comorbidities. Early detection, long-term risk reduction. 1–6


World's first dual-chamber discrimination algorithm.

Dual Sensor™

Twin trace is designed to physiologically modulate the heart rhythm by combining Accelerometer and Minute Ventilation sensors.

SonR™ CRT Optimization

SonR™ measures real-time LV contractilty1 to optimize AV & VV delays.


Brady Tachy OverlapTM – BTOTM

96% specificity in slow VT zone.9

A proof of Parad+TM discrimination performance.

Multipoint Pacing™

Capture a broader area of LV,10 reduce persistent mechanical dyssynchrony11 and improve hemodynamics.12

  1. Stockburger M, et al. Long-term clinical effects of ventricular pacing reduction with a changeover mode to minimize ventricular pacing in general population (ANSWER study). European Heart Journal. 2015;36:151–57.
  2. Andersen HR, et al. Long-term follow-up of patients from a randomized trial of atrial versus ventricular pacing for sick-sinus syndrome. Lancet. 1997;350:1210–16.
  3. Skanes AC, et al. Progression to chronic atrial fibrillation after pacing: The Canadian Trial Of Physiologic Pacing (CTOPP). J Am Coll Cardiol. 2001;38:167–72.
  4. Nielsen J, et al. A randomized comparison of atrial and dual chamber pacing in 177 consecutive patients with sick sinus syndrome. J Am Coll Cardiol. 2003; 42: 614–23.
  5. Sweeney M, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation. 2003;107:2932–37.
  6. Wilkoff BL, et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID trial). JAMA. 2002;288:3115–23.
  7. Stockburger M, et al. Safety and efficiency of ventricular pacing prevention with an AAI-DDD changeover mode in patients with sinus node disease or atrioventricular block: impact on battery longevity-a substudy of the ANSWER trial. Europace 2016;18:739–46.
  8. Benkemoun H, et al. Optimizing pacemaker longevity with pacing mode and settings programming: results from a pacemaker multicenter registry. Pacing Clin Electrophysiol 2012;35:403–08.
  9. Sadoul N, et al. Incidence and clinical relevance of slow ventricular tachycardia in implantable cardioverter-defibrillator recipients: an international multicenter prospective study. Circulation. 2005;16;112:946–53. 
  10. Menardi E, et al. Characterization of ventricular activation pattern and acute hemodynamics during multipoint left ventricular pacing. Heart Rhythm. 2015;12:1762–69
  11. Rinaldi CA, et al. Acute effects of multisite left ventricular pacing on mechanical dyssynchrony in patients receiving cardiac resynchronization therapy. J Card Fail. 2013;19:731–38.
  12. Thibault B, et al. Acute haemodynamic comparison of multisite and biventricular pacing with a quadripolar left ventricular lead. Europace. 2013;15:984–91.
Exemplary message

By continuing to browse this website you confirm that you are a healthcare professional.